Public procurement notice: Voluntary Ex Ante Transparency Notice
Published: 2020-12-18
Buyer: Sykehusinnkjøp HF
Country: NO
Contract type: Supplies
Procedure: Contract award without prior publication
CPV classification: 33600000: Pharmaceutical products
Estimated value: 300000 NOK
Award criteria: Lowest price

Technical requirements: Sykehusinnkjøp HF, Divisjon legemidler (LIS) is collecting tenders for medicines that are used by the Health Trusts. LIS has previously announced and implemented an open tender competition for non-parenteral special pharmaceutical preparations (LIS 2001b). The contest includes active ingredients in accordance with the tender documentation, annex 3: the Active ingredients list.
A new need has arisen after the contracts were signed for contracts for the delivery of Prednisolon tablets 20 mg (ATC code H02AB06) as the selected supplier has announced that the delivery of their product cannot be maintained.
Based on this, LIS intends to enter into contracts between the regional health trusts (the Contracting Authorities) and Orifarm Generics AS (the Supplier) as a supplementary contract to LIS 2001b, i.e., the scope and length of the contract will follow the mentioned procurement (including access to extensions and terminations), without a new contest being held for this ingredient. The health companies that are under the regional health trusts have an option to enter into the contracts.
LIS has explored the market situation and is of the opinion that it is not possible to hold a new contest or that a supplier other than Orifarm Generics AS can deliver the product in the same contract period, and that the situation that has occurred is not the contracting authority’s fault, nor something that the Contracting Authority could foresee. LIS therefore believes that there are grounds to make the procurement without a competition. Refer to the public procurement regulation § 21-5, cf. § 21-2, cf. § 13-4 letter b No. 3 and letter cf. also § 13-3 letter e.
LIS requests that those who have objections to this submit feedback before the waiting period expires on 23 December 2020. If no objections are received, contracts will be signed after the waiting period has expired.
LIS intends to enter into contracts between the regional health trusts (the Contracting Authorities) and Orifarm Generics AS (the Supplier) as a supplementary contract to LIS 2001b. I.e., the scope and length of the contract will follow the mentioned procurement (including access to extensions and terminations), without a new contest being held for this ingredient. The health companies that are under the regional health trusts have an option to enter into the contracts.
LIS has explored the market situation and is of the opinion that it is not possible to hold a new contest or that a supplier other than Orifarm Generics AS can deliver the product in the same contract period, and that the situation that has occurred is not the contracting authority’s fault, nor something that the Contracting Authority could foresee. LIS therefore believes that there are grounds to make the procurement without a competition. Refer to the public procurement regulation § 21-5, cf. § 21-2, cf. § 13-4 letter b No 3 and letter cf. also § 13-3 letter e.
LIS requests that those who have objections to this submit feedback before the waiting period expires on 23 December 2020. If no objections are received, contracts will be signed after the waiting period has expired.


Winner: Orifarm Generics AS
Award value: 300000